



Citra-Lock™

**Safe &
Effective**

**Catheter
Lock
Solution**

prefilled syringe



Citra-Lock™ S

**Anti Biofilm
Reducing infection
Anti Coagulant**

4% trisodium citrate



Dirinco®
Always innovating




The **safe** way to lock every central catheter

Citra-Lock™ 4% is recommended in the European Renal Best Practice Guidelines (ERBP) and by the American Society of Diagnostic and Interventional Nephrology (ASDIN).

Citrate locks have been extensively studied.

Citra-Lock™ 4% offers the best benefit/risk ratio.



Clinical advantages of Citra-Lock™ 4% (compared to heparin):

- safe
- avoids heparin-associated bleeding
- improves reliability of INR assays (prothrombin time - time/international normalised ratio)
- safe for heparin induced thrombocytopenia (HIT patients)
- no side effect

REFERENCES:

1. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking, Marcel C. Weijmer, Yvette J. Debets-Ossenkopp, Francien J. van de Vondervoort and Piet M. ter Wee, Department of Nephrology and Department of Medical Microbiology and Infection Control, Vrije Universiteit Medical Center, Amsterdam, The Netherlands, *Nephrol Dial Transplant* (2002) 17: 2189–2195
2. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study, Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P
3. Risk of heparin lock-related bleeding when using indwelling venous catheters in haemodialysis, Hüseyin Karaaslan, Pierre Peyronnet, Daniel Benevent, Christian Lagarde, Michel Rince, Claude Leroux-Robert, Service de Néphrologie CHU Dupuytren, Limoges, France, *Nephrol Dial Transplant*, (2001) 16: 2072-2074
4. A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters, Hendrickx L, Kuypers D, Evenepoel P, Maes B, Messiaen T, Vanrenterghem Y, Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium. *Int J Artif Organs* 2001 Apr;24(4):208-11
5. Concentrated Sodium Citrate (23%) for Catheter Lock, Stephen R. Ash, Rita A. Mankus, James M. Sutton, Ruth E. Criswell, Carol C. Crull, Katherine A. Velasquez, Brian D. Smeltzer, Todd S. Ing, Greater Lafayette Healthcare Services, Inc. (previously St. Elizabeth Medical Center and Lafayette Home Hospital); Arnett Clinic, Lafayette; HemoCleanse, Inc. and Ash Medical Systems, Inc., West Lafayette, Indiana; University of Illinois, Chicago, Illinois, U.S.A. *Hemodial Int* 2000;4: 22-31
6. Sodium citrate 4% locking solution in hemodialysis patients with central venous catheters, Calantha K. Yon and Chai L. Low, *Am J Health-Syst Pharm.* 2013; 70:131-6
7. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP), Raymond Vanholder¹, Bernard Canaud², Richard Fluck³, Michel Jadoul⁴, Laura Labriola⁵, A. Marti-Monros⁶, J. Tordoir⁶ and W. Van Biesen¹
¹Nephrology Section, Department of Internal Medicine, University Hospital, Gent, Belgium, ²Nephrology, Dialysis and Intensive Care Unit, Lapeyronie University Hospital, Montpellier, France, ³Department of Renal Medicine, Royal Derby Hospital, Derby, UK, ⁴Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, ⁵Nephrology Department, Consorcio Hospital General Universitario, Valencia, Spain and ⁶Vascular Surgery, Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands *NDT Plus* (2010) 3: 234–246 doi: 10.1093/ndtplus/sfq041
8. Morphometric and biological characterization of biofilm in tunneled hemodialysis catheters, Jones SM, Ravani P, Hemmelgarn BR, Muruve D, Macrae JM. Division of Nephrology, University of Calgary, Calgary, Alberta, Canada. *Am J Kidney Dis.* 2011 Mar;57(3):449-55. Epub 2011 Jan 22.
9. Sodium citrate 4% locking solution for central venous dialysis catheters—an effective, more cost-efficient alternative to heparin, Linda Grudzinski¹, Patricia Quinan¹, Sophie Kwok¹ and Andreas Pierratos^{1,2} Department of Nephrology, Humber River Regional Hospital and ²Department of Medicine, University of Toronto, Toronto, Ontario, Canada, *Nephrol Dial Transplant* (2007) 22: 471–476
10. Trisodium citrate 4%—an alternative to heparin capping of haemodialysis catheters, Charmaine E. Lok, Debra Appleton, Cynthia Bhola, Brian Khoo and Robert M. A. Richardson, Department of Medicine, Division of Nephrology, The Toronto General Hospital, *Nephrol Dial Transplant.* (2007) 22 (2): 477-483.
11. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces, Robert M. Q. Shanks¹, Jennifer L. Sargent¹, Raquel M. Martinez¹, Martha L. Graber² and George A. O'Toole¹ ¹Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, NH 03755 and ²Department of Medicine, Section of Hypertension and Nephrology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03766, USA. *Nephrol Dial Transplant* (2006) 1 of 9 doi:10.1093/ndt/gfl170

The **effective** way to lock every central catheter



Citra-Lock™ 4% is effective in maintaining catheter patency.

**Trisodium Citrate 4% (TSC) works as an anti-coagulant
and decreases the incidence of infection.**

Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters

Yon et al, Am J Health-Syst Pharm. 2013; 70:131-6

Outcome	Heparin (n=60)	Sodium Citrate (n=60)	p
No. CRIs*	20	11	0.026
No. CRIs/1000 catheter-days	1.90	0.81	0.026
Organisms isolated from CRIs			
Enterobacter species	5	0.55	
MSSA	5	2	0.25
Other gram-positive species	4	2	0.42
Other gram-negative species	4	2	0.42
Pseudomonas aeruginosa	3	0	0.087
No. hospitalizations related to CRIs	16	9	0.064
No. thrombosis episodes	41	40	0.24
No. alteplase administrations	41	40	0.24
No. catheters exchanged or removed	34	18	0.002
No. catheters exchanged/1000 catheter-days	3.24	1.33	0.002



Clinical advantages of Citra-Lock™ 4% (compared with heparin):

- reduction of clotting and tPA use
- better outcomes over catheter exchange
- reduces biofilm
- reduction of hospitalisation
- cost efficient



**Anti Biofilm
Reducing infection
Anti Coagulant**

4% trisodium citrate



Citra-Lock™

Safe & Effective

Catheter Lock Solution

Increase safety & Simplify handling

www.citra-lock.com to watch the Citra-Lock™ instruction video



Citra-Lock™ 4%
5ml vial



Boxes contain
20 x 5ml vials

Art.nr. Citra-Lock™ 4%: 24060201

CE 0197



Citra-Lock™S 4%
2,5ml syringe

Boxes contain
120 x 2,5ml syringes

Art.nr. Citra-Lock™S 4% pre-filled syringe: 24060200

CE 0344

ORDERING INFORMATION:
Please email your enquiry to info@citra-lock.com. We will direct you to our local distributor.

Also Available: Citra-Lock™ 30%
Citra-Lock™ 46,7%

Citra-Lock™ is a Dirinco product and registered as a Medical Device



www.citra-lock.com
info@citra-lock.com

 **Dirinco®**
Always innovating

Dirinco BV • Oss • The Netherlands